FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alexandre Zlotta

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Prostate

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Stéphane Larré; Yair Lotan; Edward M Messing; Shahrokh F Shariat; Mark S Soloway; Robert S Svatek; Alexandre R Zlotta; James W F Catto; Michael S Cookson; H Barton Grossman
Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.
Sean C Skeldon; Theodorus H Van Der Kwast; Bas W G van Rhijn; Melyssa Aronson; Bharati Bapat; Peter Bostrom; Jim Catto; Zane Cohen; Andrew Evans; Neil E Fleshner; Steven Gallinger; Sally Hanna; Spring Holter; Michael A Jewett; Cynthia Kuk; Aaron Pollett; Kara Semotiuk; Shahrokh F Shariat; Alexandre R Zlotta
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Nathan Perlis; Polat Turker; Peter J Bostrom; Antonio Finelli; Neil E Fleshner; Michael A S Jewett; Cynthia Kuk; Girish Kulkarni; Tuomas Mirtti; Alexandre R Zlotta
Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alexandre Zlotta (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Stéphane Larré; Yair Lotan; Edward M Messing; Shahrokh F Shariat; Mark S Soloway; Robert S Svatek; Alexandre R Zlotta; James W F Catto; Michael S Cookson; H Barton Grossman
Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.
European urology 2013;63(6):1049-58.
2013: Sean C Skeldon; Theodorus H Van Der Kwast; Bas W G van Rhijn; Melyssa Aronson; Bharati Bapat; Peter Bostrom; Jim Catto; Zane Cohen; Andrew Evans; Neil E Fleshner; Steven Gallinger; Sally Hanna; Spring Holter; Michael A Jewett; Cynthia Kuk; Aaron Pollett; Kara Semotiuk; Shahrokh F Shariat; Alexandre R Zlotta
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
European urology 2013;63(2):379-85.
2013: Nathan Perlis; Polat Turker; Peter J Bostrom; Antonio Finelli; Neil E Fleshner; Michael A S Jewett; Cynthia Kuk; Girish Kulkarni; Tuomas Mirtti; Alexandre R Zlotta
Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.
World journal of urology 2013;31(1):161-7.
2013: Alexandre R Zlotta
Bladder cancer: Validating what we've got.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2013;7(1-2):33-4.
2012: David R Yates; Alexandre R Zlotta; Maurizio Brausi; James W F Catto; Guido Dalbagni; Morgan Rouprêt; Shahrokh F Shariat; Richard J Sylvester; J Alfred Witjes; Juan Palou Redorta
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
European urology 2012;62(6):1088-96.
2012: David Horovitz; Michael A Jewett; Cynthia Kuk; Girish Kulkarni; Tuomas Mirtti; Martti Nurmi; Polat Turker; Peter J Bostrom; Antonio Finelli; Neil E Fleshner; Alexandre R Zlotta
Does patient age affect survival after radical cystectomy?
BJU international 2012;110(11 Pt B):E486-93.
2012: Bas W G van Rhijn; André N Vis; Tahlita C M Zuiverloon; Ellen C Zwarthoff; Sultan S Alkhateeb; Chris H Bangma; Bharati Bapat; Peter J Bostrom; Neil E Fleshner; Michael A S Jewett; Liyang Liu; Madelon N M van der Aa; Theo H van der Kwast; Alexandre R Zlotta
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
BJU international 2012;110(8):1169-76.
2012: Ekaterina Olkhov-Mitsel; Hilmi Ozcelik; Franz Recker; Theodorus Van der Kwast; Alexandre R Zlotta; Laurent Briollais; Eleftherios P Diamandis; Neil E Fleshner; Ken J Kron; Maciej Kwiatkowski; Christine Massey; Bharati Bapat
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.
Epigenetics : official journal of the DNA Methylation Society 2012;7(9):1037-45.
2012: Polat Turker; Bas W G van Rhijn; Marcelo L Wroclawski; Peter J Bostrom; Andy Evans; Antonio Finelli; Neil E Fleshner; Michael A Jewett; Hannes Kortekangas; Cynthia Kuk; Theo Vander Kwast; Matti Laato; Tuomas Mirtti; Joan Sweet; Alexandre R Zlotta
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
BJU international 2012;110(6):804-11.
2012: Alexandre R Zlotta; Robert K Nam
To biopsy or not to biopsy--thou shall think twice.
European urology 2012;61(6):1115-7; discussion 1117-8.
2012: Alexandre R Zlotta
Editorial comment.
The Journal of urology 2012;187(5):1606; discussion 1606-7.
2011: Peter J Bostrom; Anjum Chagpar; Raymond Chow; Antonio Finelli; Neil E Fleshner; Ethan D Grober; Kelly Lane; Laura Legere; Justin Liu; Paul J Toren; Tran Truong; Hao Xi; Alexandre R Zlotta; Michael A S Jewett
Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records.
Journal of the American Medical Informatics Association : JAMIA 2011;18(6):835-41.
2011: Greg Trottier; Theodorus H van der Kwast; Alexandre R Zlotta; Nathan Lawrentschuk; Monique J Roobol; Ants Toi; Peter J Boström; Karen Chadwick; Andrew Evans; Kimberly A Fernandes; Antonio Finelli; Neil E Fleshner
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
BJU international 2011;108(8 Pt 2):E237-44.
2011: Sultan S Alkhateeb; Sas Bar-Moshe; Peter J Bostrom; Neil Fleshner; Sally Hanna; Michael Jewett; David M Kakiashvili; Mischel Neill; Michel Petein; Bas Van Rhijn; Sandrine Rorive; Thierry Roumeguere; Claude Schulman; Shahrokh F Shariat; Alexandre R Zlotta
Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin.
Urology annals 2011;3(3):119-26.
2011: Carmen Mir; Hiroshi Miyamoto; Juan Morote; Shahrokh F Shariat; Sean Skeldon; Rati Vajpeyi; Theodorus H van der Kwast; Bas W G van Rhijn; Jorge Yao; Sultan Alkhateeb; Raheela Ashfaq; Peter Bostrom; Andrew Evans; Neil Fleshner; Sally Hanna; Michael Jewett; Cynthia Kuk; Yair Lotan; Ed Messing; Alexandre R Zlotta
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.
BJU international 2011;108(1):24-30.
2011: Alexandre R Zlotta; Thierry Roumeguere; Cynthia Kuk; Sultan Alkhateeb; Sandrine Rorive; Anne Lemy; Theodorus H van der Kwast; Neil E Fleshner; Michael A S Jewett; Antonio Finelli; Claude Schulman; Yair Lotan; Shahrokh F Shariat; Joelle Nortier
Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer.
European urology 2011;59(6):1026-31.
2011: Antonio Finelli; Greg Trottier; Nathan Lawrentschuk; Robert Sowerby; Alexandre R Zlotta; Lenny Radomski; Narhari Timilshina; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Micheal A S Jewett; John Trachtenberg; Neil E Fleshner
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
European urology 2011;59(4):509-14.
2011: Alexandre R Zlotta
What is the future of virtual cystoscopy in urology?
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2011;5(1):38-9.
2011: David M Kakiashvili; Bas W G van Rhijn; Greg Trottier; Michael A S Jewett; Neil Fleshner; Antonio Finelli; Julian Azuero; Chris H Bangma; Rati Vajpeyi; Sultan Alkhateeb; Sally Hanna; Alex Kostynsky; Cynthia Kuk; Theodorus H Van Der Kwast; Alexandre R Zlotta
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
BJU international 2011;107(4):540-6.
2010: Alexandre R Zlotta
Word of wisdom. Re: a sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.
European urology 2010;58(6):943-4.
2010: Peter J Boström; Sultan Alkhateeb; Bas W G van Rhijn; Cynthia Kuk; Alexandre R Zlotta
Optimal timing of radical cystectomy in T1 high-grade bladder cancer.
Expert review of anticancer therapy 2010;10(12):1891-902.
2010: N Lawrentschuk; G Trottier; C Kuk; Alexandre R Zlotta
Role of surgery in high-risk localized prostate cancer.
Current oncology (Toronto, Ont.) 2010;17 Suppl 2():S25-32.
2010: Sultan S Alkhateeb; Bas W G van Rhijn; Antonio Finelli; Theodorus van der Kwast; Andrew Evans; Sally Hanna; Rati Vajpeyi; Neil Fleshner; Michael A S Jewett; Alexandre R Zlotta
Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
The Journal of urology 2010;184(1):81-6.
2010: Bas W G van Rhijn; Theo Van der Kwast; David M Kakiashvili; Neil Fleshner; Madelon N M van der Aa; Sultan Alkhateeb; Chris H Bangma; Michael A S Jewett; Alexandre R Zlotta
Pathological stage review is indicated in primary pT1 bladder cancer.
BJU international 2010;106(2):206-11.
2010: Alexandre R Zlotta
Should urologists always perform a bladder cuff resection during nephroureterectomy, and which method should they use?
European urology 2010;57(6):970-2.
2010: Bas W G van Rhijn; Geert J L H van Leenders; Bert C M Ooms; Wim J Kirkels; Alexandre R Zlotta; Egbert R Boevé; Adriaan C Jöbsis; Theo Van der Kwast
The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.
European urology 2010;57(6):1052-7.
2010: Sultan Saud Alkhateeb; Shabbir M Alibhai; Antonio Finelli; Neil E Fleshner; Michael A Jewett; Alexandre R Zlotta; John Trachtenberg
Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?
Urology annals 2010;2(2):58-62.
2010: Alexandre R Zlotta; Samuel M Cohen; Colin Dinney; Michael Droller; Theo Van der Kwast; Bas W G van Rhijn; Bernard H Bochner; Gilad Ameil; Michael A S Jewett
BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer.
Urologic oncology 2010;28(3):329-33.
2009: Alexandre R Zlotta; Neil E Fleshner; Michael A Jewett
The management of BCG failure in non-muscle-invasive bladder cancer: an update.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2009;3(6 Suppl 4):S199-205.
2009: Michael Ordon; Scott Boerner; Alexandre R Zlotta; Michael A S Jewett; Neil Fleshner
The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma.
BJU international 2009;104(11):1641-5.
2009: Bas W G van Rhijn; Maximilian Burger; Yair Lotan; Eduardo Solsona; Christian G Stief; Richard J Sylvester; J Alfred Witjes; Alexandre R Zlotta
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.
European urology 2009;56(3):430-42.
2009: John M Fitzpatrick; Claude Schulman; Alexandre R Zlotta; Fritz H Schröder
Prostate cancer: a serious disease suitable for prevention.
BJU international 2009;103(7):864-70.
2009: Mischel G Neill; Sree Appu; Alexandre R Zlotta
Strategies to preserve prostate health.
Drugs of today (Barcelona, Spain : 1998) 2009;45(1):63-80.
2008: Theo Van der Kwast; Alexandre R Zlotta; Neil Fleshner; Michael Jewett; Antonio Lopez-Beltran; Roldolfo Montironi
Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2008;30(6):309-15.
2008: Amit Gupta; Pierre I Karakiewicz; Claus G Roehrborn; Yair Lotan; Alexandre R Zlotta; Shahrokh F Shariat
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7385-90.
2008: Mireia Musquera; Neil E Fleshner; Antonio Finelli; Alexandre R Zlotta
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Expert review of anticancer therapy 2008;8(7):1073-9.
2008: Abdullah M Al-Ghamdi; Gina Lockwood; Ants Toi; Girish S Kulkarni; Andres Evans; Antonio Finelli; Alexandre R Zlotta; Neil Fleshner
Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.
The Journal of urology 2008;179(4):1332-4.
2008: Shahrokh F Shariat; Jochen Walz; Claus G Roehrborn; Alexandre R Zlotta; Paul Perrotte; Nazareno Suardi; Fred Saad; Pierre I Karakiewicz
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1526-31.
2008: Mischel G Neill; Rohan Shahani; Alexandre R Zlotta
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy.
Therapeutics and clinical risk management 2008;4(1):11-8.
2007: Alexandre R Zlotta
When and how to treat superficial and muscle-invasive bladder cancer.
European urology 2007;52(6):1554-7.
2007: Neil Fleshner; Alexandre R Zlotta
Prostate cancer prevention: past, present, and future.
Cancer 2007;110(9):1889-99.
2007: Vincenzo Scattoni; Alexandre R Zlotta; Rodolfo Montironi; Claude Schulman; Patrizio Rigatti; Francesco Montorsi
Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature.
European urology 2007;52(5):1309-22.
2007: Renaud Bollens; Alberto Rosenblatt; Baldo P Espinoza; Alexandre De Groote; Thierry Quackels; Thierry Roumeguere; Marc Vanden Bossche; Eric Wespes; Alexandre R Zlotta; Claude C Schulman
Laparoscopic partial nephrectomy with "on-demand" clamping reduces warm ischemia time.
European urology 2007;52(3):804-09.
2007: Rohan Shahani; Neil E Fleshner; Alexandre R Zlotta
Pharmacotherapy for prostate cancer: the role of hormonal treatment.
Discovery medicine 2007;7(39):118-24.
2007: Bob Djavan; Vincent Ravery; Bernardo Rocco; Alexandre R Zlotta; Maurizio Brausi; Markus Margreiter; Peter Hammerer; Amir Kaisary; Theodore Anagnostou; Imre Romics; Piotr Dobronski; Ottavio De Cobelli; Michael Marberger
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005.
BJU international 2007;100 Suppl 2():22-5.
2007: Shahrokh F Shariat; Alexandre R Zlotta; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(4):445-59.
2007: Cora N Sternberg; michael krainer; William K Oh; Sergio Bracarda; Joaquim Bellmunt; Haluk Ozen; Alexandre R Zlotta; Tomasz M Beer; Stéphane Oudard; Michael Rauchenwald; Iwona Skoneczna; Markus M Borner; John M Fitzpatrick
The medical management of prostate cancer: a multidisciplinary team approach.
BJU international 2007;99(1):22-7.
2006: Alexandre R Zlotta; Claude Schulman
Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out.
Nature clinical practice. Urology 2006;3(9):474-5.
2006: Sas Barmoshe; Alexandre R Zlotta
Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments.
Expert opinion on pharmacotherapy 2006;7(13):1685-99.
2006: Sas Barmoshe; Alexandre R Zlotta
How do I treat and follow my TUNA patients.
World journal of urology 2006;24(4):397-404.
2006: Alexandre R Zlotta
Random biopsies in bladder tumors: in most cases, you shall not!
European urology 2006;50(2):186-93.
2006: Alexandre R Zlotta
Words of wisdom. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.
European urology 2006;49(4):757-8.
2006: Alexandre R Zlotta
Words of wisdom. Differential exoprotease activities confer tumor-specific serum peptidome patterns.
European urology 2006;49(4):756-7.
2006: Alexandre R Zlotta
Prostate cancer: fine tuning our ability to accurately grade and stage the disease prior to therapy.
European urology 2006;49(1):8-10.
2005: Thierry Roumeguère; Thierry Quackels; Renaud Bollens; A de Groote; Alexandre R Zlotta; M Vanden Bossche; Claude Schulman
Trans-obturator vaginal tape (TOT) for female stress incontinence: one year follow-up in 120 patients.
European urology 2005;48(5):805-9.
2005: Alexandre R Zlotta; Pierre Teillac; Jean Pierre Raynaud; Claude C Schulman
Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
European urology 2005;48(2):269-76.
2005: Pierre Teillac; Aldo V Bono; Jacques Irani; Manfred P Wirth; Alexandre R Zlotta
The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
Clinical therapeutics 2005;27(3):273-85.
2005: Jacques Irani; Laurent Salomon; Michel Soulié; Alexandre R Zlotta; Alexandre de la Taille; Bertrand Doré; Christine Millet
Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
Urology 2005;65(3):533-7.
2005: Alexandre R Zlotta
Fluorescence cystoscopy: is flexible scope as effective as rigid?
European urology 2005;47(3):318.
2005: Kossen M Ho; Renaud Bollens; Thierry Roumeguere; M Vanden Bossche; Alexandre R Zlotta; Claude C Schulman
Modified specimen retrieval facilitates urethro-vesical anastomosis in laparoscopic radical prostatectomy.
BJU international 2005;95(3):447-9.
2005: Judd W Moul; Alexandre R Zlotta
Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
BJU international 2005;95(3):285-90.
2004: Alexandre R Zlotta; Thierry Roumeguère; Vincent Ravery; Paul Hoffmann; Francesco Montorsi; Levent Türkeri; Michael Dobrovrits; Vincenzo Scattoni; Samuel Ekane; Renaud Bollens; Marc Vanden Bossche; Bob Djavan; Laurent Boccon-Gibod; Claude C Schulman
Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients.
European urology 2004;46(1):42-9.
2004: Bob Djavan; Alexandre R Zlotta; Claude Schulman; Pierre Teillac; Peter Iversen; Laurent Boccon-Gibod; Georg Bartsch; Michael Marberger
Chemotherapeutic prevention studies of prostate cancer.
The Journal of urology 2004;171(2 Pt 2):S10-3; discussion S13-4.
2003: Thierry Roumeguère; Renaud Bollens; Thierry Quackels; M Vanden Bossche; Alexandre R Zlotta; Claude C Schulman
[Laparoscopy in urology].
Revue médicale de Bruxelles 2003;24(5):400-7.
2003: Mesut Remzi; Theodore Anagnostou; Vincent Ravery; Alexandre R Zlotta; Carsten Stephan; Michael Marberger; Bob Djavan
An artificial neural network to predict the outcome of repeat prostate biopsies.
Urology 2003;62(3):456-60.
2003: Alexandre R Zlotta; Xenofon Giannakopoulos; Odd Maehlum; Tonnes Ostrem; Claude C Schulman
Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.
European urology 2003;44(1):89-93.
2003: Alexandre R Zlotta; Mesut Remzi; Peter B Snow; Claude C Schulman; Michael Marberger; Bob Djavan
An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
The Journal of urology 2003;169(5):1724-8.
2003: Thierry Roumeguere; Renaud Bollens; Marc Vanden Bossche; Dan Rochet; David Bialek; Paul Hoffman; Thierry Quackels; Amir Damoun; Eric Wespes; Claude C Schulman; Alexandre R Zlotta
Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches.
World journal of urology 2003;20(6):360-6.
2003: Brian J Duggan; John J McKnight; Kate E Williamson; Maurice Bernard Loughrey; Declan O'Rourke; Peter W Hamilton; Samuel R Johnston; Claude C Schulman; Alexandre R Zlotta
The need to embrace molecular profiling of tumor cells in prostate and bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1240-7.
2003: Claude C Schulman; Alexandre R Zlotta
Prevention of prostate cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;163():199-211; discussion 264-6.
2003: Bob Djavan; Judd W Moul; Alexandre R Zlotta; Mesut Remzi; Vincent Ravery
PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.
European urology 2003;43(1):12-27.
2002: Bob Djavan; Mesut Remzi; Alexandre R Zlotta; Vincent Ravery; Peter Hammerer; Andreas Reissigl; Piotr Dobronski; Amir Kaisary; Michael Marberger
Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Urology 2002;60(4 Suppl 1):4-9.
2002: Bob Djavan; Mesut Remzi; Claude C Schulman; Michael Marberger; Alexandre R Zlotta
Repeat prostate biopsy: who, how and when?. a review.
European urology 2002;42(2):93-103.
2002: Renaud Bollens; Thierry Roumeguere; Marc Vanden Bossche; Thierry Quackels; Alexandre R Zlotta; Claude C Schulman
Comparison of laparoscopic radical prostatectomy techniques.
Current urology reports 2002;3(2):148-51.
2002: Bob Djavan; Mesut Remzi; Alexandre R Zlotta; Christian Seitz; Peter Snow; Michael Marberger
Novel artificial neural network for early detection of prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):921-9.
2002: Wim P J Witjes; Jean J M C H de la Rosette; Annelise van den Berg-Segers; David Colongo; Gary G Koch; Alexandre R Zlotta; Alexandre Colau; Michel J A M de Wildt; Hessel Wijkstra
Computerised assessment of maximum urinary flow: an efficient, consistent and valid approach.
European urology 2002;41(2):206-13; discussion 213.
2002: Claude Schulman; Renaud Bollens; Thierry Roumeguere; Marc Vanden Bossche; Alexandre R Zlotta
[The urology department].
Revue médicale de Bruxelles 2002;23 Suppl 2():175-7.
2002: Alexandre R Zlotta; Bob Djavan
Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data.
Current opinion in urology 2002;12(1):7-14.
2001: Bob Djavan; Vincent Ravery; Alexandre R Zlotta; Piotr Dobronski; Michael Dobrovits; Mitra Fakhari; Christian Seitz; Martin Susani; A Borkowski; Laurent Boccon-Gibod; Claude C Schulman; Michael Marberger
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
The Journal of urology 2001;166(5):1679-83.
2001: Claude C Schulman; Samuel Ekane; Alexandre R Zlotta
Nutrition and prostate cancer: evidence or suspicion?
Urology 2001;58(3):318-34.
2001: Bob Djavan; Matthias Waldert; Alexandre R Zlotta; Piotr Dobronski; Christian Seitz; Mesut Remzi; A Borkowski; Claude Schulman; Michael Marberger
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.
The Journal of urology 2001;166(3):856-60.
2001: Renaud Bollens; Marc Vanden Bossche; Thierry Roumeguere; A Damoun; Samuel Ekane; Paul Hoffmann; Alexandre R Zlotta; Claude C Schulman
Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases.
European urology 2001;40(1):65-9.
2001: Bob Djavan; Peter R Mazal; Alexandre R Zlotta; Robert Wammack; Vincent Ravery; Mesut Remzi; Martin Susani; A Borkowski; S Hruby; Laurent Boccon-Gibod; Claude C Schulman; Michael Marberger
Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
The Prostate 2001;47(2):111-7.
2001: Alexandre R Zlotta; Samuel Ekane; Claude C Schulman
[Can we prevent prostatic cancer: role of nutrition?].
Revue médicale de Bruxelles 2001;22(2):87-92.
2000: Claude C Schulman; J E Altwein; Alexandre R Zlotta
Treatment options after failure of local curative treatments in prostate cancer: a controversial issue.
BJU international 2000;86(9):1014-22.
2000: Claude C Schulman; Frans M J Debruyne; G Forster; F P Selvaggi; Alexandre R Zlotta; Wim P J Witjes
4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
European urology 2000;38(6):706-13.
2000: Alexandre R Zlotta; Jean-Paul Van Vooren; Olivier Denis; Annie Drowart; Mamadou Daffé; Philippe Lefèvre; Liliane Schandene; M de Cock; J De Bruyn; Paul Vandenbussche; Fabienne Jurion; Kamiel Palfliet; J Simon; Claude C Schulman; Jean Content; Kris Huygen
What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?
International journal of cancer. Journal international du cancer 2000;87(6):844-52.
2000: Bob Djavan; Alexandre R Zlotta; Samuel Ekane; Mesut Remzi; Gero Kramer; Thierry Roumeguère; M Etemad; R Wolfram; Claude C Schulman; Michael Marberger
Is one set of sextant biopsies enough to rule out prostate Cancer? Influence of transition and total prostate volumes on prostate cancer yield.
European urology 2000;38(2):218-24.
2000: Alexandre R Zlotta; Claude C Schulman
Neoadjuvant and adjuvant hormone therapy for prostate cancer.
World journal of urology 2000;18(3):179-82.
2000: Alexandre R Zlotta; Jean-Paul Van Vooren; Kris Huygen; Annie Drowart; M Decock; M Pirson; Fabienne Jurion; Kamiel Palfliet; Olivier Denis; J Simon; Claude C Schulman
What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
European urology 2000;37(4):470-7.
2000: Bob Djavan; Alexandre R Zlotta; Mesut Remzi; K Ghawidel; A Basharkhah; Claude C Schulman; Michael Marberger
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
The Journal of urology 2000;163(4):1144-8; discussion 1148-9.
2000: Alexandre R Zlotta; Claude C Schulman
Biological markers in superficial bladder tumors and their prognostic significance.
The Urologic clinics of North America 2000;27(1):179-89, xi-xii.
2000: Alexandre R Zlotta; Samuel Ekane; Claude C Schulman
[Prostate cancer and nutrition].
Acta urologica Belgica 2000;68(1):6-9.
2000: Alexandre R Zlotta; Claude C Schulman
Biological response modifiers for the treatment of superficial bladder tumors.
European urology 2000;37 Suppl 3():10-5.
1999: Bob Djavan; Alexandre R Zlotta; Mesut Remzi; K Ghawidel; B Bursa; S Hruby; R Wolfram; Claude C Schulman; Michael Marberger
Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
Urology 1999;54(5):846-52.
1999: Alexandre R Zlotta; Bob Djavan; M Damoun; Thierry Roumeguere; Michel Petein; K Entezari; Michael Marberger; Claude C Schulman
The importance of measuring the prostatic transition zone: an anatomical and radiological study.
BJU international 1999;84(6):661-6.
1999: Alexandre R Zlotta; Claude Schulman
[Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
Revue médicale de Bruxelles 1999;20(4):A201-5.
1999: Bob Djavan; Alexandre R Zlotta; Christian Kratzik; Mesut Remzi; Christian Seitz; Claude C Schulman; Michael Marberger
PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.
Urology 1999;54(3):517-22.
1999: Bob Djavan; Mesut Remzi; Alexandre R Zlotta; Christian Seitz; R Wolfram; S Hruby; B Bursa; Claude C Schulman; Michael Marberger
Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Techniques in urology 1999;5(2):71-6.
1999: Alexandre R Zlotta; Jean-Christophe Noel; Isabelle Fayt; Annie Drowart; Jean-Paul Van Vooren; Kris Huygen; J Simon; Claude C Schulman
Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
The Journal of urology 1999;161(3):792-8.
1999: Alexandre R Zlotta; Claude C Schulman
Interstitial laser coagulation for the treatment of benign prostatic hyperplasia using local anaesthesia only.
BJU international 1999;83(3):341-2.
1999: Alexandre R Zlotta; Claude C Schulman
BPH and sexuality.
European urology 1999;36 Suppl 1():107-12.
1999: Alexandre R Zlotta; Claude C Schulman
Clinical evolution of prostatic intraepithelial neoplasia.
European urology 1999;35(5-6):498-503.
1998: Alexandre R Zlotta; Bob Djavan; Michel Petein; M Susani; Michael Marberger; Claude C Schulman
Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
The Journal of urology 1998;160(6 Pt 1):2089-95.
1998: Bob Djavan; Alexandre R Zlotta; G Byttebier; S Shariat; M Omar; Claude C Schulman; Michael Marberger
Prostate specific antigen density of the transition zone for early detection of prostate cancer.
The Journal of urology 1998;160(2):411-8; discussion 418-9.
1998: Alexandre R Zlotta; Claude C Schulman
[Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone].
Revue médicale de Bruxelles 1998;19(3):119-23.
1998: Bob Djavan; Martin Susani; S Shariat; Alexandre R Zlotta; DE Silverman; Claude C Schulman; Michael Marberger
Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate.
Techniques in urology 1998;4(2):103-9.
1998: Alexandre R Zlotta; Annie Drowart; Jean-Paul Van Vooren; H Shekarsarai; M de Cock; M Pirson; Kamiel Palfliet; Fabienne Jurion; J Simon; Claude C Schulman; Kris Huygen
Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.
The Journal of urology 1998;159(6):1885-91.
1998: Alexandre R Zlotta; Bob Djavan; C Matos; Jean-Christophe Noel; MO Peny; DE Silverman; Michael Marberger; Claude C Schulman
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer.
British journal of urology 1998;81(2):265-75.
1998: Alexandre R Zlotta; Claude C Schulman
Etiology and diagnosis of prostate cancer: what's new? A review.
European urology 1998;33(4):351-8.
1997: Bob Djavan; Alexandre R Zlotta; Martin Susani; G Heinz; S Shariat; DE Silverman; Claude C Schulman; Michael Marberger
Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination.
Urology 1997;50(6):986-92; discussion 992-3.
1997: Alexandre R Zlotta; Thierry Wildschutz; G Raviv; MO Peny; Daniel Van Gansbeke; Jean-Christophe Noel; Claude C Schulman
Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience.
Journal of endourology / Endourological Society 1997;11(4):251-8.
1997: Alexandre R Zlotta; Annie Drowart; Kris Huygen; J De Bruyn; H Shekarsarai; M Decock; M Pirson; Fabienne Jurion; Kamiel Palfliet; Olivier Denis; Françoise Mascart; J Simon; Claude C Schulman; Jean-Paul Van Vooren
Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
Clinical and experimental immunology 1997;109(1):157-65.
1997: Alexandre R Zlotta; Bob Djavan; Michael Marberger; Claude C Schulman
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction.
The Journal of urology 1997;157(4):1315-21.
1997: Thierry Roumeguere; Alexandre R Zlotta; B R Djavan; M Marberger; Claude C Schulman
[PSA level of the transitional zone: a new marker especially reliable for the detection of prostatic cancer].
Acta urologica Belgica 1997;65(1):5-9.
1997: H Shekarsarai; Alexandre R Zlotta; Annie Drowart; Jean-Paul Van Vooren; M de Cock; M Pirson; Kamiel Palfliet; Fabienne Jurion; A Vanonckelen; J Simon; Claude C Schulman; Kris Huygen
[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
Acta urologica Belgica 1997;65(1):1-4.
1997: Alexandre R Zlotta; G Raviv; MO Peny; Jean-Christophe Noel; J Haot; Claude C Schulman
Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study.
The Journal of urology 1997;157(3):894-9.
1997: Alexandre R Zlotta; Annie Drowart; Jean-Paul Van Vooren; M de Cock; M Pirson; Kamiel Palfliet; Fabienne Jurion; A Vanonckelen; J Simon; Claude C Schulman; Kris Huygen
Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
The Journal of urology 1997;157(2):492-8.
1997: Claude C Schulman; Thierry Wildschutz; Alexandre R Zlotta
Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions.
European urology 1997;32 Suppl 3():41-7.
1996: G Raviv; T Janssen; Alexandre R Zlotta; F Descamps; Alain Verhest; Claude C Schulman
Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer.
The Journal of urology 1996;156(3):1050-4; discussion 1054-5.
1996: G Raviv; Alexandre R Zlotta; T h Janssen; F Descamps; JP Vanegas; Alain Verhest; Claude C Schulman
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Cancer 1996;77(10):2103-8.
1996: Alexandre R Zlotta; MO Peny; C Matos; Claude C Schulman
Transurethral needle ablation of the prostate: clinical experience in patients in urinary acute retention.
British journal of urology 1996;77(3):391-7.
1996: G Raviv; T Janssen; Alexandre R Zlotta; L Louis; F Descamps; Alain Verhest; Claude C Schulman
[High-grade intraepithelial prostatic neoplasms: diagnosis and association with prostate cancer].
Acta urologica Belgica 1996;64(1):11-5.
1996: Alexandre R Zlotta; G Raviv; MO Peny; JP Vanegas; Claude C Schulman
[A new method of cancer treatment: the use of radiofrequencies in urological tumors].
Acta urologica Belgica 1996;64(1):1-5.
1996: Alexandre R Zlotta; G Raviv; Claude C Schulman
Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia.
European urology 1996;30(2):249-55.
1995: C C Schulman; Alexandre R Zlotta
TUNA: a promising new therapy for BPH.
Contemporary urology 1995;7(10):59-60, 62, 64 passim.
1995: Roland F Van Velthoven; Michel Petein; Willem Oosterlinck; C Zandona; Alexandre R Zlotta; A P Van der Meijden; Jean-Lambert Pasteels; H Roels; Claude Schulman; Robert Kiss
Image cytometry determination of ploidy level, proliferative activity, and nuclear size in a series of 314 transitional bladder cell carcinomas.
Human pathology 1995;26(1):3-11.
1995: Claude C Schulman; Alexandre R Zlotta
Transurethral needle ablation of the prostate (TUNA). A new treatment of benign prostatic hyperplasia using interstitial radiofrequency energy.
Journal d'urologie 1995;101(1):33-6.
1995: Claude C Schulman; Alexandre R Zlotta
Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience.
Urology 1995;45(1):28-33.
1994: L A Hourriez; Alexandre R Zlotta; Claude C Schulman
Transurethral needle ablation (TUNA): histopathological, radiological and clinical studies of a new office procedure for treatment of benign prostatic hyperplasia.
Acta urologica Belgica 1994;62(4):33-8.
1994: Claude Schulman; Alexandre R Zlotta
Transurethral needle ablation of the prostate (TUNA): pathological, radiological and clinical study of a new office procedure for treatment of benign prostatic hyperplasia using low-level radiofrequency energy.
Archivos españoles de urología 1994;47(9):895-901.
1994: Alexandre R Zlotta; Annie Drowart; J P van Vooren; J Simon; Claude C Schulman; Kris Huygen
Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Acta urologica Belgica 1994;62(3):63-8.
1994: C C Schulman; Alexandre R Zlotta
Transurethral needle ablation of the prostate (TUNA): pathological, radiological and clinical study of a new office procedure for treatment of benign prostatic hyperplasia using low-level radiofrequency energy.
Seminars in urology 1994;12(3):205-10.
1994: Roland F Van Velthoven; Michel Petein; Alexandre R Zlotta; Willem Oosterlinck; A van der Meijden; C Zandona; H Roels; Jean-Lambert Pasteels; Claude Schulman; Robert Kiss
Computer-assisted chromatin texture characterization of Feulgen-stained nuclei in a series of 331 transitional bladder cell carcinomas.
The Journal of pathology 1994;173(3):235-42.
1994: Claude C Schulman; Alexandre R Zlotta
Transurethral needle ablation (TUNA): histopathological, radiological and clinical studies of a new office procedure for treatment of benign prostatic hyperplasia.
Progress in clinical and biological research 1994;386():479-86.
1993: Alexandre R Zlotta; Robert Kiss; R Vanvelthoven; Jean-Christophe Noel; Michel Petein; D Ardichvili; Jean-Lambert Pasteels; Claude Schulman
DNA histogram typing in human seminomas.
Anticancer research 1993;13(5C):1867-71.
1993: Claude C Schulman; Alexandre R Zlotta; J S Rasor; L Hourriez; Jean-Christophe Noel; S D Edwards
Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia.
European urology 1993;24(3):415-23.
1993: J S Rasor; Alexandre R Zlotta; S D Edwards; Claude C Schulman
Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia.
European urology 1993;24(3):411-4.